Sanofi (SNY) and J&J (JNJ) present data for Type 2 diabetes treatments that show they're...

|About: Sanofi (SNY)|By:, SA News Editor

Sanofi (SNY) and J&J (JNJ) present data for Type 2 diabetes treatments that show they're more effective in lowering blood-sugar levels than Merck's (MRK) $3.3B market leader Januvia. However, Lantus from Sanofi, which is already approved, and canagliflozin from J&J, which isn't, have their drawbacks.